Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using doing procedures leading to effective results with a minimal number of treatment applications are also described.

An improvement to the effectiveness or take of skin grafts or tissue replacements used to treat wounds is provided. A therapeutic composition comprising recombinant human platelet-derived growth factor BB homodimer (rhPDGF-BB) and a porous biocompatible carrier is first applied to the wound surface, followed by applying a skin substitute or tissue replacements composition.

Provided are therapeutic formulations and methods of use thereof.

Provided are therapeutic formulations and methods of use thereof.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.

A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO.sub.2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection. This material herein enters into chemical, physical, and biological interactions with the corresponding biological systems. It can herein be decomposed, and can act as a supplier for the silicic acid required for metabolism. Furthermore, it can have a supportive or shielding effect. It can be present as a granulate, microparticles, fiber, and as a woven or nonwoven fabric produced therefrom, or as a layer on implants or wound dressings. The material can be used as a medical device or as a nutritional supplement.

A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO.sub.2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection. This material herein enters into chemical, physical, and biological interactions with the corresponding biological systems. It can herein be decomposed, and can act as a supplier for the silicic acid required for metabolism. Furthermore, it can have a supportive or shielding effect. It can be present as a granulate, microparticles, fiber, and as a woven or nonwoven fabric produced therefrom, or as a layer on implants or wound dressings. The material can be used as a medical device or as a nutritional supplement.

Provided herein are hemostatic compositions useful for treating wounds in a patient in need thereof. An exemplary hemostatic comprises gelatin or a derivative thereof and silicate nanoparticles. Methods of use, kits comprising the compositions, and a process of making the compositions are also provided.

A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

A solution blow spin device includes a syringe pump assembly, an airbrush adapter, and a handle base. The syringe pump assembly, airbrush adapter, and handle base are reversibly coupled to one another and configured to work in tandem to address wound dressing using a polymer solution and autologous skin cell suspension co-spray. The airbrush adapter includes multiple nozzles for deposition of multiple solutions sequentially or simultaneously in order to improve would dressing efficacy. The syringe pump assembly includes multiple syringes holding the multiple solutions, and the syringes can be emptied by individually addressable lead screws configured to translate blocks to depress syringe plungers when the lead screws are rotated via corresponding actuators.